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Background: Preoperative neutrophil-to-lymphocyte ratio (NLR) has been identified as a predictor for the recurrence
of hepatocellular carcinoma (HCC), but the cut-off of NLR is inconsistent in various studies. Thus, we detected the
prognostic value of preoperative NLR in the single-nodule small HCC (SHCC) patients using X-tile for cutpoint.
Methods: Between January 2007 and December 2010, a total of 222 single-nodule SHCC patients underwent curative
resection and were examined for the prognostic roles of preoperative NLR by X-tile.
Results: In this study, all patients were divided into the low-NLR subgroup (NLR≤ 2.1) and the high-NLR subgroup
(NLR > 2.1) by X-tile. Preoperative NLR showed predictive value for time to recurrence (TTR) and overall survival (OS).
Moreover, NLR was associated with total bilirubin, white blood cell counts, and HBsAg, respectively (P = 0.012, <0.001,
and 0.011, respectively). Especially, NLR could discriminate the outcome of patients in the subgroup with alpha-
fetoprotein (AFP) levels of ≤400 ng/mL. Importantly, postoperative transcatheter arterial chemoembolization (TACE)
had close relationship with OS (P = 0.001) and TTR (P≤ 0.001).
Conclusions: Therefore, this study indicates that preoperative NLR, divided by X-tile for the cutpoint, is a simple
prognostic marker for the patients with single-nodule SHCC after curative resection.
Keywords: Liver cancer, Inflammation, Neutrophil, Lymphocyte, PrognosisBackground
Hepatocellular carcinoma (HCC) is a typical inflammation-
related malignancy mainly induced by hepatitis B or C viral
(HBV or HCV) infection and is the major challenge and
cancer burden for China’s health system [1–3]. Surgical re-
section is still the mainstay of curative treatment. Although
surgical techniques and perioperative care are improved
recently, the long-term clinical outcomes of HCC remain
disappointing owing to a high recurrence rate after
surgical resection [4, 5]. To date, many biomarkers
have been developed to provide information about
the prognosis and treatment of HCC [6–9]. However,* Correspondence: duchengyou@126.com
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even though normal serum AFP is found in 30 to
40 % of HCC patients [10]. Therefore, it is of great
urgent for us to set up reliable and convenient prog-
nostic biomarkers to select optimal candidates to
adopt preventive and therapeutic strategies and screen
the prognosis of patients at risk.
Recently, there are increasing evidences that metachro-
nous carcinogens are affected by inflammatory activity
and the malignant potential of cancer cells are the import-
ant causes of HCC recurrence [11, 12]. Notably, accu-
mulating evidences demonstrated that imbalance of the
systemic inflammatory response orchestrated a tumor-
supporting microenvironment and led to upregulation of
the inflammatory process for patients with HCC [13–15],
via some molecular pathways related with apoptosis inhib-
ition, DNA damage repair, and angiogenesis promotions distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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environment in HCC composed of various inflammatory/
immune cells including neutrophil [20], macrophages
[21], Treg [22], and Th17 [7] lymphocytes which were
closely related with the prognosis of HCC. Consistent with
this work, neutrophil-to-lymphocyte ratio (NLR) was also
identified as a marker of systemic inflammation response
associated with the prognosis of various cancers such as
colorectal cancer [23], pancreatic cancer [24], gastric can-
cer [25], and HCC [26]. Of particular note in HCC, NLR
showed good predictive abilities for patients who under-
went curative resection [27], liver transplantation [28],
transcatheter arterial chemoembolization (TACE) [29],
and radiofrequency ablation [30]. To our knowledge, there
is no study on the association between the predictive role
of NLR and the patients with single-nodule small HCC
(SHCC). Additionally, the cut-off value of NLR is not con-
sistent, which is commonly set at five empirically [31],
mean value [32], or determined by receiver operating
characteristic curve [26] and significant associated hazard
ratio [28]. These different selections would hinder the
clinical application and comparative study of NLR in dif-
ferent patient populations. Thus, in this study, we used
“minimum P value” approach [33, 34] by X-tile software, a
bio-informatics tool for biomarker assessment, to get an
optimal cut-off value of NLR and evaluate the correlation
of preoperative NLR with prognosis in single-nodule
SHCC patients following curative resection.
Methods
Patients and follow-up
A total of 222 patients included in this retrospective co-
hort study were randomly selected from 256 consecutive
patients with pathologically confirmed HCC who were
eligible for surgical resection in The First Affiliated Hos-
pital of Chongqing Medical University from 2007 to
2010. Thirty-four patients were excluded according to
the following inclusion and exclusion criteria: (1) pri-
mary SHCC with a single tumor ≤5 cm, (2) Child-Pugh
A liver reserve function, (3) complete laboratory test
data, (4) the absence of preoperative extrahepatic metas-
tases, (5) no preoperative anticancer treatments, (6)
tumor-free surgical margins, (7) complete patient re-
cords and follow-up data, and (8) survival for more than
30 days. The study was approved by the Ethics Commit-
tee of The First Affiliated Hospital of Chongqing Med-
ical University, and written informed consents were
obtained from all patients.
Sixty-nine patients underwent TACE in 1 month after
surgery because they met the eligibility criteria for post-
operative TACE in our department as follows: (1) age 18
to 70 years old, (2) Child-Pugh A or B liver function, (3)
no severe coagulopathy (platelet count ≥50 × 109/L or
prothrombin activity ≥40 %), (4) no obstructive jaundice,and (5) Eastern Cooperative Oncology Group cores ≤2.
TACE was carried out by clinicians with more than
10 years of experience. Briefly, a highly selective 5-F
catheter was used to assess the arterial blood supply to
the liver by visceral angiography. Then, a mixture of
three chemotherapeutic agents including 200 mg oxali-
platin, 40 mg epirubicin, and 160 mg irinotecan was
used for hepatic artery infusion chemotherapy. And
then, 5 mL of Lipiodol was injected. After embolization,
the extent of vascular occlusion was determined and
blood flow in other arterial vessels was assessed by
angiography.
Postoperatively, all patients were followed up every
1–6 months according to the postoperative time with
serum alpha-fetoprotein (AFP) and abdominal CT or/
and MRI. Tumor recurrences were diagnosed based
upon the combined findings of typical CT or MRI ap-
pearance and elevated AFP level. Time to recurrence
(TTR) [35] was defined as the interval that recurrence
was first confirmed after surgery. Overall survival (OS)
was the interval from the first operation to death or the
latest follow-up visit. The median follow-up time was
42.4 months in these patient populations. Tumor-node-
metastasis (TNM) classification system of International
Union Against Cancer (edition 7) and tumor characteris-
tics, such as tumor capsule formation and vascular inva-
sion, were assessed as described previously [11].
Selection of cut-off value for NLR
Here, “minimum P value” approach [33, 34] was applied
to estimate an optimal cut-off of NLR for the best separ-
ation of patients’ TTR by X-tile software [36], version
3.6.1 (Yale University, New Haven, CT). Subsequently,
the prognostic significance of the NLR level in single-
nodule SHCC was investigated. X-tile software was de-
veloped by Robert et al. from Yale University in 2004
[36]. X-tile plots can divide a population into three levels
(low, medium, and high level) and separate a single co-
hort into training and validation subgroups for P value
estimation. This software shows the users an “on-the-fly”
histogram which can provide an associated Kaplan-Meier
curve, and the best P value is available after rigorous stat-
istical evaluation by X-tile.
Statistic analysis
Results were presented as the mean ± SD. For the com-
parison of variables, t test, χ2 test, and Spearman ρ coef-
ficient test were carried out as appropriate, respectively.
Medium of age, alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), total bilirubin (TB), cre-
atinine, platelet counts, neutrophil counts, lymphocyte
counts, and white blood cell (WBC) were used as cut-off
values. Univariate analysis and multivariate Cox propor-
tional hazards model were used to estimate OS and
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16.0 (SPSS, Inc., Chicago, IL), and a two-tailed P value
less than 0.05 was considered significant.
Results
Baseline characteristics
The baseline characteristics of 222 SHCC patients with
single nodule were described in Table 1. Among them,
there were 189 men and 33 women with the average age
of 53 years. The median follow-up time was 42.4 months.
Of the 222 incident of SHCC cases, median tumor size
was 3.0 cm. A total of 114 patients had tumor ≤3.0 cm
in diameter, and 108 patients had tumor >3.0 cm in
diameter. According to the TNM staging system, 44
(19.8 %) patients in our study populations belonged to
stage IIIA (44/222). The median values of lymphocyte
counts, neutrophil counts, WBC counts, and NLR were
1.5 × 109/L, 2.9 × 109/L, 5.2 × 109/L, and 1.9, respectively.
Some laboratory tests were found to be higher than nor-
mal values. For example, median values of ALT (normal
value is 40 U/L) and AST (normal value is 40 U/L) were
39 and 33 U/L, respectively.Table 1 Characteristics of patients according to NLR
Characteristics NLR
≤2.1 (n = 130) >
Gender (male vs female) 111 vs 19
Age 52.0 ± 11.3
Albumin (g/L) 41.81 ± 5.13
ALT (U/L) 59.88 ± 82.22
AST (U/L) 39.25 ± 20.63
TB (mg/dL) 0.84 ± 0.34
Cr (mg/dL) 0.87 ± 0.17
Lymphocyte counts (109/L) 1.80 ± 0.66
Neutrophil counts (109/L) 2.59 ± 0.83
WBC counts (109/L) 4.90 ± 1.45
HBsAg (positive vs negative) 118 vs 12
Anti-HCV (positive vs negative) 1 vs 129
AFP (ng/mL) (≤20 vs >20) 51 vs 79
INR 1.02 ± 0.077
Platelet counts (109/L) 137.36 ± 57.08
Vascular invasion (yes vs no) 25 vs 105
Tumor differentiation (I–II vs III–IV) 94 vs 36
Tumor encapsulation (yes vs no) 50 vs 80
Tumor size (≤3.0 vs >3.0) 74 vs 56
TNM stage (I–II vs IIIA) 108 vs 22
Postoperative TACE (yes vs no) 37 vs 93
Re-operation (yes vs no) 10 vs 120
NLR neutrophil-to-lymphocyte ratio, ALT alanine aminotransferase, AST aspartate am
hepatitis B surface antigen, AFP alpha-fetoprotein, INR international normal ratio, TNA best cut-off value for NLR
According to the “minimum P value” approach, X-tile
software was applied to estimate the optimal cut-off of
NLR for the best separation of patients’ TTR (Fig. 1).
Here, P = 0.002 was minimum P value when NLR arrived
at 2.1, which subsequently was identified as the best cut-
off point of NLR for operative recurrence. Accordingly,
all the patients were divided into two groups: a low-NLR
group (≤2.1, n = 130) and a high-NLR group (>2.1, n =
92, Table 1).Correlation of NLR with clinicopathologic features
As shown in Table 1, preoperative NLR was associated
with some clinical pathologic characteristics. Old SHCC
patients had higher incidence to have elevated NLR (P =
0.049). Moreover, NLR (low vs high) was related with
several laboratory tests rather than tumor factor, such as
TB, WBC, and HBsAg (P = 0.012, <0.001 and 0.011, re-
spectively). No obvious correlation with gender, ALT,
AST, TB, creatinine, and platelet counts was observed
(all P > 0.05).P
2.1 (n = 92)
78 vs 14 NS
55.1 ± 10.0 0.049
42.13 ± 4.77 NS
64.65 ± 110.44 NS
54.99 ± 83.46 NS
1.16 ± 1.08 0.012
0.98 ± 0.78 NS
1.20 ± 0.50 <0.001
4.70 ± 2.61 <0.001
6.49 ± 2.79 <0.001
72 vs 20 0.011
0 vs 92 NS
40 vs 52 NS
1.03 ± 0.09 NS
134.16 ± 62.42 NS
24 vs 68 NS
73 vs 19 NS
45 vs 47 NS
40 vs 52 NS
70 vs 22 NS
32 vs 60 NS
6 vs 86 NS
inotransferase, TB total bilirubin, Cr creatinine, WBC white blood cell, HBsAg
M tumor-node-metastasis, TACE transarterial chemoembolization
Fig. 1 X-tile plots of NLR on single-nodule small hepatocellular carcinoma following curative resection. The X-tile plots show the χ2 log-rank
values with cutpoint, producing low and high subgroups. a The X-axis represents all potential cut-off values from low to high (left to right) that
define a low subset, whereas the Y-axis represents cut-off values from high to low (top to bottom) that define a high subset. Red coloration of
cut-off values indicates an inverse correlation with time to recurrence, and green coloration represents direct associations. The optimal cut-off
value occurs at the brightest pixel (green or red). b A histogram of the entire cohort divided into low and high subgroups according to the
optimal cut-off value of NLR (2.1). c The statistical significance of relative risk (RR) generally assessed by Cox proportional hazards model. The X-axis
represents all potential cut-off values from low to high (left to right), and the Y-axis of the graph is log of the relative risks. The red line is the
optimal cutpoint of NLR (2.1). d A Kaplan-Meier plot of NLR for time to recurrence produced by the optimal cut-off value of NLR. Blue represents
the low subgroup, and gray represents the high subgroup
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The 1-, 3-, and 5-year OS of these single-nodule SHCC pa-
tients were 94.1, 82.9, and 65.4 %, respectively, and the 1-,
3-, and 5-year TTR rates were 85.4, 66.7, and 45.9 %, re-
spectively. On univariate analyses of our data, international
normal ratio (INR), platelet counts, and neutrophil countsTable 2 Prediction of survival and recurrence of patients with a sing
Factors OS
Univariate multivariate
P HR (95 % CI)
Age (≤53 vs >53) NS
AFP(≤20 vs >20) NS
INR (≤1.0 vs >1.0) 0.010
PLT counts (≤127 vs >127) 0.046
Neutrophil counts 0.040 0.329 (0.174–0.623)
Vascular invasion (yes vs no) NS
Tumor size (≤3.0 vs >3.0) 0.040
Postoperative TACE (yes vs no) 0.001 2.566 (1.488–4.424)
Re-operation (yes vs no) NS
NLR (>2.1 vs ≤2.1) 0.014 3.013 (1.633–5.561)
Univariate analysis Kaplan-Meier method, Multivariate analysis Cox proportional haza
AFP alpha-fetoprotein, INR international normal ratio, PLT platelet, TACE transarterial
TTR time to recurrence, HR hazard ratio, NS not significant, NA not adoptedwere demonstrated to be related with OS (P = 0.010, 0.046,
and 0.040, respectively). Old age, AFP, vascular invasion,
and re-operation showed association with TTR (P = 0.004,
0.043, 0.001, and <0.001, respectively). Moreover, tumor
size, postoperative TACE, and preoperative NLR had prog-
nostic significance for both OS (P = 0.040, 0.001, and 0.014,le nodule of SHCC following curative resection
TTR
Univariate multivariate






NA 0.001 1.757 (1.110–2.781) 0.016
NS <0.001 NS
0.001 <0.001 2.175 (1.408–3.359) <0.001
NA <0.001 9.037 (4.970–16.432) <0.001
<0.001 0.002 1.619 (1.057–2.478) 0.027
rds regression model, SHCC small hepatocellular carcinoma,
chemoembolization, NLR neutrophil-to-lymphocyte ratio, OS overall survival,
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spectively, Table 2 and Fig. 2).
Then, multivariate analyses were used to examine
the association between significant clinical factors
and NLR. Neutrophil counts showed higher predict-
ive value on OS (P = 0.001). Vascular invasion and re-
operation were all independent predictors for TTR
(P = 0.016 and <0.001, respectively). Importantly, both
postoperative TACE and preoperative NLR had close
relationship with OS (P = 0.001 and <0.001, respect-
ively) and TTR (P = <0.001 and 0.027, respectively).
In addition, the prognostic significance of preopera-
tive NLR also applied to SHCC patients with low
AFP levels of ≤400 ng/mL by stratified analyses
(P = 0.007 for TTR and 0.009 for OS, respectively,
Fig. 3).
Discussion
Cancer is characterized by complex tissues closely re-
lated with chronic inflammatory contributing to progres-
sive development and high postoperative recurrence riskFig. 2 Prognostic values of preoperative neutrophil-to-lymphocyte ratio (N
a, b Kaplan-Meier estimates of time to recurrence (TTR) and overall surviva
2.1) subgroups, respectively. c, d TTR (c) and OS (d) of patients with or with[1]. There are increasing evidences that systemic inflam-
mation is responsible for the tumor-promoting activities
and associated with the recurrence of certain tumors
[16, 17]. Recently, as a typical systematic inflammatory
biomarker, NLR has also been identified as a predictor
for the outcomes of various tumors [23–26]. However,
the reported cut-off values of NLR were different in vari-
ous studies, which could not provide a consistent stand-
ard for comparison among different patient populations.
Therefore, for the first time, we used X-tile software, a
bio-informatics tool especially for biomarker assessment,
to determine the cut-off value of NLR in single-nodule
SHCC patients. In this study, we clearly observed that
using X-tile, high preoperative NLR could predict the
poor survival of SHCC patients with single nodule after
hepatectomy. This result revealed that even in small and
single tumor, systematic inflammatory responses play
critical roles and exist along the path of HCC progres-
sion. Moreover, we also found that postoperative TACE
could improve the outcomes of patients with single-
nodule SHCC. However, the choice of postoperativeLR) and postoperative transcatheter arterial chemoembolization (TACE).
l (OS) of NLR which were divided into low (NLR≤ 2.1) and high (NLR >
out postoperative TACE by Kaplan-Meier analyses, respectively
Fig. 3 Kaplan-Meier analyses of neutrophil-to-lymphocyte ratio (NLR) in the low AFP subgroup (≤400 ng/mL). NLR was divided into low (NLR≤
2.1) and high (NLR > 2.1) subgroups by X-tile. In the low AFP subgroup (≤400 ng/mL), NLR could predict time to recurrence (a) and overall
survival (b), respectively
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a randomized procedure, and the further randomized
controlled trial with larger sample size from multicenter
is necessary.
X-tile software was developed by Robert et al. [36],
aiming to assess the biological relationships between
biomarkers and outcomes of certain diseases. This tool
could produce corrected P values to evaluate statistical
significance of data assessed by multiple cutpoints. Con-
sistent with previous applications [7, 9], X-tile produced
an optimal cut-off of NLR which presents an accurate
prognostic factor in cases of SHCC with single nodule.
We believe that there is no unique preoperative NLR
that satisfies all patient populations of the world. X-tile
could provide objective and accurate cut-off of NLR to
investigate its association with the recurrence of single-
nodule SHCC.
In the present study, we found that NLR was associ-
ated to some laboratory parameters, such as TB
(P = 0.012), HBsAg (P = 0.011), and WBC (P < 0.001). On
one hand, the close relationship between NLR and WBC
demonstrated that NLR was an inflammation-related
biomarker and could accurately reflect an inflammatory
status. On the other hand, as well known, one of the typ-
ical features of HCC is a high frequency of hepatitis B or
C viral (HBV or HCV) infection and subsequently fibro-
sis or cirrhosis. As mentioned above, high NLR reflects
aggravated inflammatory status of SHCC patients, ma-
jority of who have poor liver function and high load of
hepatitis viral infection. Therefore, to some extent, TB
and HBsAg could respond to this disease condition. Al-
though there was no association between NLR and
tumor factors, we thought that it was the reason of the
selection of patients who all were single-nodule SHCC
and had better tumor differentiation (I–II vs III–IV, 167vs 55) and earlier tumor stage (I–II vs IIIA, 178 vs 44).
After all, among these patients, tumor-promoting in-
flammation would overwhelm antitumor immunity with
the development of tumor.
Although the precise tumor-promoting inflammatory
mechanisms related with NLR remain to be clear, our
previous studies and other investigations could provide
several possible explanations for the predictive value of
NLR. First, previous study found that intratumoral neu-
trophils could serve as a predictor for HCC recurrence
[20]. This result was consistent with other reports that
neutrophils promoted tumor invasion and formation of
hepatic metastasis via mutual interactions with HCC
cells [37] and circulating tumor cells [38]. We therefore
assume that neutrophil-mediated mechanisms are in-
volved in extracellular matrix remodeling [20], growth
factors [20], and initial angiogenic switch [39] contribut-
ing to reroute the inflammatory response into a tumor-
promoting direction. Second, elevated NLR usually rep-
resents relative lymphocytopenia. As we know, the host’s
anticancer immune response greatly depends on lym-
phocytes. Various types of lymphocytes such as intratu-
moral regulatory T cells [22], Th17 cells [7], and
gammadelta T cells [40] constituted the immunosuppres-
sive network within the tumor milieu and may promote
proliferation and metastatic activity of tumor cells by the
roles in cytotoxic cell death and cytokine production [41].
Third, increased NLR may stand for the imbalance be-
tween tumor-promoting inflammation (neutrophils) and
antitumor immunity (lymphocytes), so that systemic in-
flammatory response has an overrepresentation, thereby
lead to a much worse prognosis for patients with SHCC.
This present study also revealed that many patients with
elevated NLR have high level of WBC, also showing
the critical role of inflammatory response in tumor
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model demonstrated that naturally activated neutro-
phils (polarized N2 phenotype) promoted tumor pro-
gression partly related with suppression of CD8+ T
cells [42]. However, studies in depth are needed to
reveal the molecular mechanisms of NLR in SHCC
development.
Here, we did not find the relationship between pre-
operative NLR and early (≤24 months) or later recur-
rence (>24 months), probably because the follow-up
period was relatively short and sample size was small.
Another explanation may be the effect of inflammatory
response in single-nodule SHCC was obstructed in
time by surgery and various treatments before it spread
out completely. Moreover, many clinical studies demon-
strated that low AFP levels of ≤400 ng/mL were a
significant favorable prognostic factor for HCC. Never-
theless, 30–40 % of HCC patients with low serum
AFP concentration had recurrence and were difficult to
monitor [43–45]. We found that preoperative NLR had
the ability to discriminate patients with worse survival
and higher recurrence rates even in the subgroup with
lower AFP levels of ≤400 ng/mL [44, 46]. Therefore,
single-nodule SHCC patients with higher preoperative
NLR and lower AFP (≤400 ng/mL) still require closer
follow-up since they have more possibilities to suffer
from tumor recurrence. But, AFP >400 ng/mL was not
shown any association with the poor outcomes of pa-
tients with single-nodule SHCC undergoing curative
resection. Considering the relative small sample size
(n = 53 for the patients with AFP >400 ng/mL), a con-
clusion about the proangiogenic role of low AFP levels
of >400 ng/mL in single-nodule SHCC should be cau-
tiously interpreted.
Thus, we believe that in the future, larger patient
population or a validation cohort with longer follow-up
period could prove it as a clinically useful or applicable
finding for patients with single-nodule SHCC treated
with curative resection. Additionally, some biomarkers
were identified as good candidates of inflammatory
markers such as C-reactive protein, Treg, and Th17 lym-
phocytes. Therefore, further comparative study in HCC
would make us better understand the predictive value of
NLR as an inflammatory index if complete data could be
obtained.Conclusions
In conclusion, we have shown that preoperative NLR, di-
vided by X-tile for the cutpoint, is a simple biomarker of
systemic inflammatory response and unfavorable prog-
nosis of single-nodule SHCC after curative resection. Al-
though we also found that postoperative TACE could
improve the outcome of patients with single-noduleSHCC, the further randomized controlled trial with lar-
ger sample size from multicenter is necessary.
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